The Enterprise Value as of November 2024 (TTM) for Viridian Therapeutics, Inc. (VRDN) is 1.42B

According to Viridian Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.42B. This represents a change of 39.51% compared to the average of 1.02B of the last 4 quarters.

Viridian Therapeutics, Inc. (VRDN) Historical Enterprise Value (quarterly & annually)

How has VRDN Enterprise Value performed in the past?

The mean historical Enterprise Value of Viridian Therapeutics, Inc. over the last ten years is 232.98M. The current 1.42B Enterprise Value has changed 60.89% with respect to the historical average. Over the past ten years (40 quarters), VRDN's Enterprise Value was at its highest in in the September 2024 quarter at 1.33B. The Enterprise Value was at its lowest in in the March 2020 quarter at -8148552.36.

Viridian Therapeutics, Inc. (VRDN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Viridian Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Viridian Therapeutics, Inc. (VRDN) Average Enterprise Value

How has VRDN Enterprise Value performed in the past?

The current Enterprise Value of Viridian Therapeutics, Inc. (VRDN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Viridian Therapeutics, Inc. (VRDN) Enterprise Value vs. Peers

How is VRDN’s Enterprise Value compared to its peers?

Viridian Therapeutics, Inc.’s Enterprise Value is less than Nuvalent, Inc. (6.38B), less than DICE Therapeutics, Inc. (1.82B), less than Arcellx, Inc. (4.79B), less than Vaxcyte, Inc. (10.01B), less than Crinetics Pharmaceuticals, Inc. (4.93B), less than Cytokinetics, Incorporated (6.54B), less than Structure Therapeutics Inc. (1.75B), greater than Icosavax, Inc. (713.87M), greater than Pliant Therapeutics, Inc. (770.48M), greater than Syndax Pharmaceuticals, Inc. (1.24B), less than Revolution Medicines, Inc. (9.43B), greater than Inozyme Pharma, Inc. (202.73M), greater than Terns Pharmaceuticals, Inc. (222.97M), less than Blueprint Medicines Corporation (6.36B), greater than 89bio, Inc. (940.63M), greater than Kura Oncology, Inc. (807.00M), less than Protagonist Therapeutics, Inc. (2.65B), less than Merus N.V. (2.68B), greater than Replimune Group, Inc. (984.10M), less than Cerevel Therapeutics Holdings, Inc. (8.24B),

Build a custom stock screener for Viridian Therapeutics, Inc. (VRDN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viridian Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Viridian Therapeutics, Inc. (VRDN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Viridian Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.